You can edit almost every page by Creating an account. Otherwise, see the FAQ.

Oxodotreotide

From EverybodyWiki Bios & Wiki

Oxodotreotide
Names
IUPAC name
Oxodotreotide
Other names
DOTA3-Tyr3-octreotate, Lutathera
Identifiers
3D model (JSmol)
ECHA InfoCard Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
E number Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
Properties
C65H87Lu3N14O19S2
Molar mass 1609.554 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Oxodotreotide[edit]

Oxodotreotide, also known as dotatate, or DOTA3-Tyr3-octreotate, is a ligand-linked somatostatin peptide analog. The peptide was invented by Jack Erion, and Ananthachari Srinivasan and others in the mid-90’s[1].

Oxodotreotide is closely related to the peptide, edotreotide, in that both molecules are identical, except at the C-terminus, where edotreotide contains a threoninol residue, and oxodotreotide contains L-threonine.[2].

Currently, the oxodotreotide name is only used in context with the radiopharmaceutical, lutetium (177Lu) oxodotreotide, which is the international nonproprietary name (INN) assigned by WHO[3].

Another radiopharmaceutical with the INN, gallium (68Ga) dotatate, is composed of the same chemical entity as lutetium (177Lu) oxodotreotide (DOTA3-Tyr3-octreotate) except that the DOTA moiety of the molecule in one case is complexed with the radionuclide, lutetium-177, and in the other case is complexed with gallium-68. The products are used to diagnose and treat patients with neuroendocrine tumors that over-express somatostatin receptors. The gallium-68 radiolabeled peptide is used as a diagnostic PET (Positron emission tomography) imaging agent, and the lutetium-177 radiolabeled peptide is used as a radiotherapeutic agent.

Both products have been developed by Advanced Accelerator Applications[4][5]

Gallium (68Ga) dotatate is approved for use in the United States for the diagnosis of neuroendocrine tumors and is marketed under the brand name, NETSPOT®®.[4]. Lutetium (177Lu) oxodotreotide has marketing approval in the EU, and also the USA [5][4]. The brand name for the product is LUTATHERA®[5]

References[edit]

  1. US 5830431, "Radiolabeled peptide compositions for site-specific targeting", assigned to Mallinckrodt Medical, Inc 
  2. De Jong M, Breeman WAP, Bakker WH, Kooij PM, Bernard BF, Hofland LJ, Visser TJ, Srinivasan A, Schmidt MA, Erion JL, Bugaj JE (1998). Comparison of 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Research, 58: 437-441 PMID 9458086
  3. https://www.whocc.no/ddd/lists_of_new_atc_ddds_and_altera/new_atc/?order_by=0&d=DESC
  4. 4.0 4.1 4.2 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504524.htm
  5. 5.0 5.1 5.2 http://www.adacap.com/wp-content/uploads/2017/09/2017-09-29-PR-EMA-Approval-Lutathera-ENG.pdf


This article "Oxodotreotide" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Oxodotreotide. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.